We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026

Dade Behring Acquires Rights to Cardiac Marker

By HospiMedica staff writers
Posted on 20 Feb 2003
A non-exclusive license under patent rights to develop, manufacture, and market immunoassays that detect a key marker of congestive heart failure (CHF) has been granted to Dade Behring (Deerfield, IL, USA) by Roche Diagnostics (Basel, Switzerland). More...
The marker is NT-proBNP (N-terminal prohormone brain natriuretic peptide).

BNP is secreted by the left ventricle when the heart is unable to pump blood efficiently. BNP dilates blood vessels and promotes sodium and water loss, reducing fluid load on the heart. Synthetic BNP (nesiritide) does not necessarily allow doctors to differentiate between elevated BNP levels due to drug treatment or due to ventricular dysfunction. In contrast, proBNP measures a hormone released when BNP is cleaved from its precursor, proBNP.

Elevated plasma NT-proBNP indicates the presence of heart failure and provides information about its severity. Also, NT-proBNP levels can help doctors identify left ventricular dysfunction, thereby allowing them to differentiate between heart failure and lung disorders with similar symptoms.

"This license enables Dade Behring, a market leader in clinical diagnostics for cardiac disease, to access an important new marker for use in the early detection and treatment of CHF,” said Jim Reid-Anderson, chairman, president, and CEO of Dade Behring.





Related Links:
Dade Behring
Roche

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Medical Adhesive
MED 5570U
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.